口腔疾病防治 (Apr 2018)

The effects of intramuscular injections of vitamin B1 and B12 on pain, salivary components and taste in pa⁃ tients with burning mouth syndrome

  • YU Xixi,
  • Lü Jian,
  • WANG Caixia,
  • WANG Yiheng,
  • DENG Songsong,
  • LI Lulu,
  • WANG Wanchun

DOI
https://doi.org/10.12016/j.issn.2096-1456.2018.04.008
Journal volume & issue
Vol. 26, no. 4
pp. 240 – 244

Abstract

Read online

Objective To determine differences in pain, salivary components and taste between burning mouth syn⁃ drome (BMS) patients and the normal population and to study the effects of intramuscular injections of vitamin B1 (VitB1) and vitamin B12 (VitB12) on BMS. Methods Before treatment: We observed and compared differences in un⁃ stimulated salivary flow rate (USFR); stimulated salivary flow rate (SSFR); salivary amylase, cortisol, and secretory im⁃ munoglobulin A (SIgA) concentrations; and taste levels between BMS patients and normal controls. After treatment: The treatment group received an intramuscular injection of 100 mg VitB1 and 0.5 mg VitB12 in the buttocks once per day for 10 days. The above indexes were recorded before and after treatment and compared. A visual analog scale (VAS) score was used to assess the degree of pain relief in patients and as a clinical evaluation index. Results Before treat⁃ ment: SSFR, salivary amylase levels and bitter taste levels of the treatment group were significantly lower than those of the control group (P 0.05). After treatment: The total effective rate of VitB1 and VitB12 on BMS was up to 70%. USFR was increased signifi⁃ cantly after treatment (P 0.05). Taste levels improved by varying de⁃ grees. Conclusions The abnormal decreases in SSFR, salivary amylase levels, and taste sensitivity and the abnormal increase in SIgA levels seen in BMS patients may be sensitive salivary indicators for the diagnosis of BMS. A VitB1 and VitB12 intramuscular injection is an effective treatment for patients with BMS, who showed pain relief. Changes in SIgA levels may be used as an indicator during follow⁃up and for the prognosis of BMS patients.

Keywords